Innovator in Mitochondrial Therapies
Founded in 2007, Stealth BioTherapeutics is a clinical-stage biopharmaceutical company developing investigational drugs for the treatment of diseases involving mitochondrial dysfunction. Our scientific focus is on the mitochondria and on the ways in which mitochondrial therapy can positively impact the lives of patients.
We are committed to positively impacting the lives of patients with novel treatment options, and to offering healthcare professionals the opportunity to transform clinical practice and patient outcomes.
Our compounds are being developed for mitochondrial diseases where there are no FDA-approved treatments, and where current approaches are often only palliative. Our lead candidate in development is elamipretide, an investigational drug which is formulated for both systemic and ophthalmic formulations, with the potential to modify disease through mitoprotection — the ability to preserve and restore normal energy production in mitochondria while decreasing oxidative stress.
The science underlying our lead investigational candidate is supported by independent, peer-reviewed publications and abstracts from internationally recognized congresses and symposia.